How India Exports Levodopa-carbidopa to the World

Levodopa-carbidopa has been a cornerstone in the treatment of Parkinson's disease in the United States. According to the FDA's Orange Book, numerous Abbreviated New Drug Applications (ANDAs) have been approved for this combination, reflecting its established presence in the market. Recent approvals include generic versions by various manufacturers, underscoring the competitive landscape. The regulatory pathway for these generics involves demonstrating bioequivalence to the reference listed drug, ensuring therapeutic equivalence.

Regarding import alerts, as of February 19, 2026, the FDA has issued Import Alert 66-41, which pertains to the detention without physical examination of unapproved new drugs promoted in the U.S. While this alert is not specific to levodopa-carbidopa, it underscores the FDA's vigilance in monitoring drug imports. Given the 21 active Indian exporters of levodopa-carbidopa, adherence to FDA regulations is paramount to ensure market access and compliance.

In the European Union, levodopa-carbidopa combinations have been authorized for the treatment of Parkinson's disease. For instance, the European Medicines Agency (EMA) granted marketing authorization for Stalevo, a combination of levodopa, carbidopa, and entacapone, on October 17, 2003. This product is indicated for adult patients with Parkinson's disease experiencing end-of-dose motor fluctuations not stabilized on levodopa/dopa-decarboxylase inhibitor treatment. Manufacturers exporting to the EU must comply with the EMA's Good Manufacturing Practice (GMP) requirements, ensuring product quality and safety.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of medicinal products. Post-Brexit, the UK has established its own regulatory framework, though it closely aligns with EU standards. Exporters must ensure compliance with MHRA guidelines to access the UK market.

Levodopa-carbidopa is listed in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in managing Parkinson's disease. The 24th edition of this list, published on September 5, 2025, includes this combination therapy. Inclusion in the WHO Model List signifies the medicine's importance in addressing global health needs. Additionally, levodopa-carbidopa formulations are standardized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy across different regions.

In India, levodopa-carbidopa is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines under the Drug Price Control Order (DPCO). As of the latest notification, the ceiling price for levodopa-carbidopa combinations has been set to ensure affordability and accessibility. Exporters are required to obtain a No Objection Certificate (NOC) from the DGFT for the export of pharmaceutical products, ensuring compliance with national regulations and monitoring of drug exports.

The primary patents for levodopa-carbidopa combinations have expired, leading to a robust generic market. This expiration has facilitated increased competition among manufacturers, resulting in more affordable options for patients globally. However, certain formulations or delivery methods may still be under patent protection, necessitating careful consideration by exporters to avoid infringement.

In the past 12 months, several developments have impacted the levodopa-carbidopa market:

1. API Price Fluctuations: In June 2025, the NPPA reported a 5% increase in the price of active pharmaceutical ingredients (APIs) for levodopa and carbidopa, attributed to supply chain disruptions.

2. Regulatory Approvals: In September 2025, the EMA approved a new generic formulation of levodopa-carbidopa, expanding treatment options within the EU.

3. Policy Changes: In December 2025, the CDSCO implemented revised guidelines for the export of pharmaceutical products, emphasizing stricter quality control measures to align with international standards.

These developments highlight the dynamic nature of the pharmaceutical industry and the importance of staying informed to navigate regulatory landscapes effectively.

India's pharmaceutical industry, often referred to as the "pharmacy of the world," heavily relies on China for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of India's API and KSM requirements are imported from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities, as any disruption in Chinese production or export policies can directly impact the availability of essential drugs.

The COVID-19 pandemic underscored these risks when Chinese factory shutdowns led to immediate shortages and price surges for common medications. For instance, the production of amoxicillin, a widely used antibiotic, depends on KSMs predominantly produced in China. Any disruption in this supply chain can cascade through global pharmaceutical production, leading to shortages.

Our proprietary trade data indicates that the top five exporters of Levodopa-carbidopa from India account for 57.4% of the total export share, with RMPL PHARMA LLP leading at 27.8%. This concentration suggests a moderate risk, as reliance on a limited number of suppliers can lead to supply disruptions if any of these entities face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, essential for antibiotics. These initiatives aim to reduce import dependence and enhance supply chain resilience.

Recent geopolitical tensions have further strained global supply chains. In March 2026, the Strait of Hormuz was blockaded following military escalations, halting maritime traffic in the Persian Gulf. This disruption has significantly impacted global trade, including the shipment of pharmaceuticals from India to key markets. (lemonde.fr) Additionally, the Red Sea and the Suez Canal have experienced increased instability, forcing shipping companies to reroute vessels around Africa's Cape of Good Hope, leading to delays and increased costs.

These disruptions have led to rising freight costs and potential delays in the delivery of pharmaceuticals, including Levodopa-carbidopa, to international markets. Such logistical challenges underscore the need for diversified supply routes and contingency planning to maintain consistent drug availability.

• Diversify API and KSM Sources: Encourage the development of alternative domestic and international suppliers to reduce dependency on a single country.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme and similar initiatives to bolster local manufacturing capabilities for critical APIs and KSMs.

• Strengthen Supplier Relationships: Foster long-term partnerships with multiple suppliers to ensure a stable and diversified supply chain.

• Develop Contingency Plans: Establish robust risk management strategies, including alternative shipping routes and inventory buffers, to mitigate the impact of geopolitical disruptions.

• Monitor Regulatory Compliance: Ensure that all suppliers adhere to international quality standards to prevent disruptions due to regulatory non-compliance.

RISK_LEVEL: MEDIUM